Professor Wang Xiaojia: More affordable, Sidabenamine offers breast cancer patients more treatment options

On April 10, 2020, the 2020 edition of the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnostic Guidelines was released in a new way through "cloud" remote video conferencingIn this update, based on the ace study in endocrine-resistant breast cancer epigenetic regulatory treatment of significant progress, China's original new drug Sidabenamine joint program in TAM treatment failure and non-steroidal AI treatment failure patients were recommended I(evidence level 1A)The application of HDAC inhibitor Sidabenamine in the field of breast cancer treatment has also attracted much attentionSidabenamine into the HR-breast cancer treatment camp, for the clinical to bring more treatment options
in breast cancer patients, HR-advanced breast cancer is currently the largest group of treatmentIn the past treatment strategies, endocrine therapy or chemotherapy is the main focusAlthough endocrine therapy recommended for such patients in accordance with the guidelines should be a priority, but due to drug accessibility and other issues, the current clinical lyme is still mainly chemotherapyIn recent years, with the introduction of fluorovis group, mTOR inhibitor iveolis and other drugs, endocrine therapy has achieved breakthrough results, better efficacy, relatively less toxicity, for HR-breast cancer patients endocrine treatment priority strategy has been truly reflectedHowever, because some drugs fail to enter the health insurance, many patients due to price factors can not use the latest endocrine-plus treatmentAnd with the introduction of China's original drug Sidabenamine, drug accessibility will be reshuffled, HR plus advanced breast cancer patients treatment options will be greatly increasedupdates to endocrinology for advanced breast cancer after menopause according to the new guidelines: for patients with the failure of tamoxifen treatment, the new HDAC inhibitor combined AI program is recommended for I, with an evidence level of 1A, while for patients with nonsteroidal AI treatment failures, the HDAC inhibitor combined AI program is also added to the I.- recommendation, and the evidence level is also 1AIn this update, sidabenamine's status in the treatment of HR-advanced breast cancer has been comprehensively upgraded, based primarily on the results of the ACE studyThe ACE study adds new milestone scant evidence for optimal treatment of HR-menopausal breast cancer patients, opening up new avenues for more TAM treatment and clinical choice for patients with failed treatment of nonsteroidal AI treatmentsWith the approval of Sidabenamine in China, it is believed that more patients with advanced HR-advanced breast cancer will benefit from epigenetic regulatory treatment ACE studies confirm the remarkable efficacy of the sidabenamine joint program on endocrine resistance
endocrine therapy as an important means in the conventional treatment of HR-positive breast cancer, in the breast cancer management process plays an important role can not be ignored For HR-menopausal advanced breast cancer, major guidelines at home and abroad recommend endocrine therapy as the preferred treatment, however endocrine resistance is a major clinical challenge Previous studies suggest that epigenetic changes are associated with disease progression and endocrine resistance to breast cancer, while HDAC inhibitor Sidabenamine can reverse epigenetic abnormalities in tumors Therefore, the application of HDAC inhibitors in the field of breast cancer treatment has attracted much attention Sidabenamine is a very good drug for T-cell lymphoma with fully independent intellectual property rights in China, and as a new drug for the treatment of breast cancer by histone deacetylase inhibitors, it is also the first in China and abroad The results of the ACE clinical study of the sidabenamine, led by Professor Jiang Zefei, for the treatment of HR-her2-stage breast cancer were reported orally at the 2018 European Society for Oncology (ESMO) annual meeting and published in the 2019 issue of The Lancet Oncology, causing a great stir at home and abroad, and Sidabenamine has thus been approved by the National Drug Administration for the treatment of advanced breast cancer treatments have higher accessibility, more choice, look forward to the early entry of Sidabenamine into health insurance
on the treatment of sidabenamine in breast cancer treatment of the drug and toxic side effects of observation and treatment and estimation can be drawn from the previous lymphoma drugs, and from the ACE study can also be observed that sidabenamine's toxic side effect is controllable, safe lack synopsis experience in the use of similar drugs because sidabenamine is the first international lysine to treat breast cancer as a histone deacetylase inhibitor In the clinical also did see some more obvious adverse reactions, such as hematological adverse reactions Therefore, the selection of the suitable population of Sidabenamine and the monitoring of adverse reactions is particularly important Because epigenetic regulation takes enough time to be effective, patients cannot be allowed to discontinue their medication prematurely due to improper handling of adverse reactions, and ultimately fail to benefit from the treatment of sidabenamine as a new class of drugs, the mechanism of the role of sidabena mine is more extensive, there are many aspects worthy of our exploration and attention It is believed that with the approval of breast cancer adaptation certificate, at the same time HR-breast cancer patients using sidabenamine for endocrine-plus treatment will be better accepted, and ultimately benefit more breast cancer patients Author: Name Source: on The of Oncology